Phio Pharmaceuticals (PHIO) Change in Accured Expenses (2011 - 2026)

Phio Pharmaceuticals (PHIO) has 16 years of Change in Accured Expenses data on file, last reported at -$215000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 365.43% year-over-year to -$215000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$153000.0 (down 77.91% YoY) and the FY2025 annual result came in at $143000.0, up 179.44% from the prior year.
• Change in Accured Expenses grew to -$215000.0 in Q1 2026, from -$246000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $436000.0 in Q3 2023 to a low of -$1.1 million in Q4 2023.
• A 5-year average of -$115882.4 and a median of -$13000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 723.08% in 2025, down 1011.11% in 2025.
• Tracing PHIO's Change in Accured Expenses over 5 years: stood at -$494000.0 in 2022, then tumbled by 130.97% to -$1.1 million in 2023, then surged by 102.37% to $27000.0 in 2024, then sank by 1011.11% to -$246000.0 in 2025, then grew by 12.6% to -$215000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$215000.0 (Q1 2026), -$246000.0 (Q4 2025), and $180000.0 (Q3 2025), per Business Quant data.